The present invention is directed to a solid ibuprofen concentrate composition and method of producing the composition. The solid ibuprofen concentrate contains (a) a solid ibuprofen free acid and (b) a solid ibuprofen alkali salt, and is characterized in that at least 90% of the weight of the solid ibuprofen concentrate is ibuprofen free acid and ibuprofen alkali salt.

There is described a composition comprised of nanoparticles of a therapeutic agent having a surface modifier adsorbed on the surface thereof. The present composition is characterized in that the therapeutic agent is ibuprofen or fenoprofen which is substantially enriched in the R(-) enantiomer.

The present invention is directed to a chemically stable pharmaceutical composition containing ibuprofen in combination with terfenadine, wherein the oxidation of terfenadine to terfenadone is prevented by the presence in the composition of an .alpha.-hydroxy carboxylic acid.

An ibuprofen composition yielding an aqueous preparation having a pH of less than 7 on the addition of water to said composition which comprises one or more medicaments including an ibuprofen medicament which forms an ibuprofen active ingredient having a melting point less than 100.degree. C., when combined with water to give an aqueous preparation having a pH of less than 7 and a phospholipid material intimately mixed with the ibuprofen medicament. The phospholipid material is capable of formin...

The present invention relates generally to the fields of chemotherapeutic treatments. More particularly, it concerns the use of ibuprofen, a non-steroid anti-inflammatory drug, in the treatments of disease. More particularly, it has been discovered that the R-enantiomer of ibuprofen, previously thought to be inactive, may be used as an antineoplastic agent and also in the prophylactic and therapeutic treatment of Alzheimer's and Alzheimer's related diseases.

Pharmaceutical compositions containing hydrocodone or a pharmaceutically acceptable acid addition salt thereof and ibuprofen or a pharmaceutically acceptable salt thereof are useful in treating pain in mammals.

Pharmaceutical compositions containing dihydrocodeine or a pharmaceutically acceptable acid addition salt thereof and ibuprofen or a pharmaceutically acceptable salt thereof are useful in treating pain in mammals.

A novel neomorphic form of ibuprofen, processes for preparing the ibuprofen, and method for administering the ibuprofen are provided. The neomorphic form is characterized by having a distinctively less bitter taste and causes less burning sensation upon swallowing. The neomorphic form of ibuprofen contains an amorphous ibuprofen. Tests indicate that the neomorphic form is less irritating to the gastrointestinal tract of animals upon administration.

The present invention is directed to a multi-layered tablet containing an ibuprofen layer, a piperidino-alkanol antihistamine layer, and a layer or layers containing conventional pharmaceutical excipients which is interspersed between the ibuprofen and piperidino-alkanol layer and serves to physically separate them. This tablet solves the problems associated with the physical and chemical incompatibilities between ibuprofen and the piperidinoalkanol antihistamines.

A water-soluble salt of ibuprofen with meglumine (N-methylglucamine) is prepared, isolate and characterized and pharmaceutical preparations containing the salt for oral administration are described which are clear, pleasant tasting liquids.